Natural Immunosuppressants as a Treatment for Chronic Insomnia Targeting the Inflammatory Response Induced by NLRP3/caspase-1/IL-1β Axis Activation: A Scooping Review
Chronic insomnia is an inflammatory-related disease with an important pathological basis for various diseases which is a serious threat to a person’s physical and mental health. So far, many hypotheses have been proposed to explain the pathogenesis of insomnia, among which inflammatory mechanisms have become the focus of scientific attention. In this regard, the aim of the present scooping review is to evaluate the potential benefits of natural compounds in treatment of chronic insomnia targeting nucleotide-binding oligomerization domain (NOD)-like receptor-pyrin-containing protein 3 (NLRP3)/caspase-1/IL-1β axis as one of the most important activators of inflammatory cascades. The data show that compounds that have the potential to cause inflammation induce sleep disorders, and that inflammatory mediators are key molecules in regulating the sleep-related activity of neurons. In the inflammatory process of insomnia, the role of NLRP3 in the pathogenesis of insomnia has been gradually considered by researchers. NLRP3 is an intracellular sensor that recognizes the widest range of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). After identification and binding to damage factors, NLRP3 inflammasome is assembled to activate the caspase-1 and IL-1β. Increased production and secretion of IL-1β may be involved in central nervous system dysregulation of physiological sleep. The current scooping review reports the potential benefits of natural compounds that target NLRP3 inflammasome pathway activity and highlights the hypothesis which NLRP3 /caspase-1/IL-1β may serve as a potential therapeutic target for managing inflammation and improving symptoms in chronic insomnia. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of neuroImmune pharmacology - 18(2023), 3 vom: 08. Aug., Seite 294-309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aghelan, Zahra [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11481-023-10078-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053414462 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053414462 | ||
| 003 | DE-627 | ||
| 005 | 20231016064603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231016s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11481-023-10078-7 |2 doi | |
| 035 | |a (DE-627)SPR053414462 | ||
| 035 | |a (SPR)s11481-023-10078-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aghelan, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Natural Immunosuppressants as a Treatment for Chronic Insomnia Targeting the Inflammatory Response Induced by NLRP3/caspase-1/IL-1β Axis Activation: A Scooping Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Chronic insomnia is an inflammatory-related disease with an important pathological basis for various diseases which is a serious threat to a person’s physical and mental health. So far, many hypotheses have been proposed to explain the pathogenesis of insomnia, among which inflammatory mechanisms have become the focus of scientific attention. In this regard, the aim of the present scooping review is to evaluate the potential benefits of natural compounds in treatment of chronic insomnia targeting nucleotide-binding oligomerization domain (NOD)-like receptor-pyrin-containing protein 3 (NLRP3)/caspase-1/IL-1β axis as one of the most important activators of inflammatory cascades. The data show that compounds that have the potential to cause inflammation induce sleep disorders, and that inflammatory mediators are key molecules in regulating the sleep-related activity of neurons. In the inflammatory process of insomnia, the role of NLRP3 in the pathogenesis of insomnia has been gradually considered by researchers. NLRP3 is an intracellular sensor that recognizes the widest range of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). After identification and binding to damage factors, NLRP3 inflammasome is assembled to activate the caspase-1 and IL-1β. Increased production and secretion of IL-1β may be involved in central nervous system dysregulation of physiological sleep. The current scooping review reports the potential benefits of natural compounds that target NLRP3 inflammasome pathway activity and highlights the hypothesis which NLRP3 /caspase-1/IL-1β may serve as a potential therapeutic target for managing inflammation and improving symptoms in chronic insomnia. Graphical Abstract | ||
| 650 | 4 | |a Chronic insomnia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IL-1β |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NLRP3 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Plant-derived immunosuppressants |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Pashaee, Somayeh |4 aut | |
| 700 | 1 | |a Abtahi, Seyed Hosein |4 aut | |
| 700 | 1 | |a Karima, Saeed |4 aut | |
| 700 | 1 | |a Khazaie, Habibolah |4 aut | |
| 700 | 1 | |a Ezati, Mohammad |4 aut | |
| 700 | 1 | |a Khodarahmi, Reza |0 (orcid)0000-0001-8375-7647 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroImmune pharmacology |d Boston, MA [u.a.] : Springer, 2006 |g 18(2023), 3 vom: 08. Aug., Seite 294-309 |w (DE-627)SPR020022093 |w (DE-600)2227405-4 |x 1557-1904 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:3 |g day:08 |g month:08 |g pages:294-309 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11481-023-10078-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 3 |b 08 |c 08 |h 294-309 | ||